22,506 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 22,506 shares of the company’s stock, valued at approximately $936,000.

Other hedge funds have also added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Moderna during the 4th quarter worth approximately $163,833,000. FMR LLC grew its holdings in Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company’s stock valued at $776,075,000 after purchasing an additional 1,282,469 shares during the period. Pictet Asset Management Holding SA increased its position in Moderna by 170.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company’s stock worth $73,447,000 after buying an additional 1,113,455 shares during the last quarter. Invesco Ltd. raised its stake in shares of Moderna by 24.3% in the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company’s stock valued at $208,169,000 after buying an additional 979,858 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Moderna by 225.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company’s stock valued at $42,027,000 after buying an additional 700,458 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $24.02 on Thursday. The stock has a 50 day moving average price of $28.52 and a 200-day moving average price of $36.08. The firm has a market capitalization of $9.29 billion, a P/E ratio of -2.59 and a beta of 1.99. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. During the same period last year, the business earned ($3.07) EPS. Moderna’s quarterly revenue was down 35.3% compared to the same quarter last year. On average, equities analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MRNA. Leerink Partners decreased their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Citigroup initiated coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a “neutral” rating and a $40.00 target price for the company. Royal Bank of Canada lowered their price target on shares of Moderna from $32.00 to $28.00 and set a “sector perform” rating on the stock in a research report on Friday, May 2nd. Barclays dropped their price target on shares of Moderna from $45.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Friday, May 2nd. Finally, UBS Group reduced their price objective on shares of Moderna from $78.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus target price of $53.95.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.